Atrogi's Oral Muscle Drug Boosts Leg Power While Cutting Fat in Small Trial
An early, uncontrolled study of ATR-258 in 13 overweight adults saw fat loss, lean mass gains and a 13% rise in leg power. A promising but preliminary signal.
Summary
Muscle loss is a major downside of today's obesity drugs, with an estimated 25–45% of weight lost on incretin-based medicines coming from lean mass. Swedish biotech Atrogi has reported early human data on ATR-258, an oral pill that targets the β2-adrenergic receptor in skeletal muscle. In an eight-week, open-label study of 13 overweight or obese adults, leg muscle power rose about 13%, fat mass fell 1.1 kg and lean mass rose 0.8 kg. The drug was well tolerated across three rising doses. The catch: there was no placebo group, the study was tiny, and it was short, so it is hard to say how much of the change came from the drug itself. Atrogi plans a Phase 2 trial in 2027 focused on muscle-sparing weight loss and sarcopenia, the age-related loss of muscle and strength. It is an interesting signal, not yet proof of benefit.
Detailed Summary
Losing weight with GLP-1 and other incretin-based drugs often costs muscle along with fat. Atrogi, a Swedish biotech, estimates that 25–45% of weight lost on these medicines may be lean mass. That matters for longevity, because muscle underpins mobility, metabolic health and independence in later life.
On 1 October, Atrogi announced human data for ATR-258, an oral drug it calls first-in-class. It targets the β2-adrenergic receptor in skeletal muscle and is designed to be "GRK2-biased," meaning it steers the receptor down one signaling route and leaves others quieter. The hope is to keep the muscle benefits of older β2-agonists while avoiding their trade-offs.
The trial enrolled 13 overweight or obese people for eight weeks. It was investigator-initiated, open-label and single-arm, so everyone knew they were taking the drug and there was no placebo comparison. Participants moved through three ascending doses, and the drug was well tolerated. Lower-extremity muscle power improved by about 13% from baseline. Fat mass fell by 1.1 kg and lean mass rose by 0.8 kg, both statistically significant. Lead investigator Morten Hostrup, who has studied this receptor for years, said the size of the leg-power signal exceeded what he has seen with classical β2-agonists.
The results build on a June 2025 Cell paper describing a 69-person Phase 1 safety study. Atrogi now plans a Phase 2 trial in 2027 testing muscle-sparing weight loss and sarcopenia. Hostrup will present the initial findings at a cachexia and sarcopenia conference in Washington, DC, in December.
The practical implication is limited for now. This is not an available treatment, and the body-composition changes are modest in absolute terms. Without a control group, placebo effects, measurement variation and training or lifestyle changes cannot be separated from the drug effect. Eight weeks and 13 people is a short, small window. Safety over longer periods, durability of benefit and real-world function remain unknown. Resistance training and adequate protein remain the proven ways to protect muscle, especially during weight loss.
Key Findings
- ATR-258, an oral GRK2-biased β2-adrenergic modulator, raised lower-extremity muscle power by about 13% in an eight-week study of 13 people.
- Mean fat mass fell 1.1 kg while lean mass rose 0.8 kg, both statistically significant but modest in absolute terms.
- The study was open-label and single-arm with no placebo group, so drug effects cannot be separated from other influences.
- Incretin-based obesity drugs may cause 25–45% of weight loss to come from lean mass, per Atrogi.
- A Phase 2 trial in muscle-sparing weight loss and sarcopenia is planned for 2027.
Methodology
This is a news report based largely on a company announcement and quotes from the trial's lead investigator and executives. The underlying evidence is an eight-week, investigator-initiated, open-label, single-arm study of 13 people, which is not peer-reviewed in this report. A prior Phase 1 trial of 69 people was published in Cell in June 2025.
Study Limitations
With no placebo control, only 13 participants and eight weeks of follow-up, the results are preliminary and prone to bias and chance. Data come from company-sourced announcements, so verify against the peer-reviewed publication or conference presentation when available. Long-term safety, durability, and effects on real-world function or in older adults and people on obesity drugs are untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: